JSPRHealthcare · BiotechnologyJSPR Stock Forecast: Jasper Therapeutics, Inc. Price Predictions for 2026-2027
The 5 Wall Street analysts covering Jasper Therapeutics, Inc. hold a median 12-month price target of $6 — +889.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
JSPR stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Jasper Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (89): Smaller than most of the companies we track.
Value (7): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Jasper Therapeutics, Inc. — and when they’d sell — is the membership.
JSPR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on JSPR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +889.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 May 2026 | RBC Capital | Maintains | Sector Perform | $4.00 → $3.00 |
| 15 May 2026 | TD Cowen | Downgrade | Hold | — |
| 1 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 23 Mar 2026 | UBS | Assumes | Neutral | $1.50 |
| 11 Nov 2025 | RBC Capital | Maintains | Sector Perform | — |
| 22 Sept 2025 | BTIG | Maintains | Buy | — |
| 22 Sept 2025 | Evercore ISI Group | Maintains | Outperform | — |
| 22 Sept 2025 | JMP Securities | Maintains | Market Outperform | — |
| 15 Aug 2025 | UBS | Maintains | Buy | — |
| 8 July 2025 | BMO Capital | Downgrade | Market Perform | — |
| 8 July 2025 | Evercore ISI Group | Maintains | Outperform | — |
| 8 July 2025 | JMP Securities | Maintains | Market Outperform | — |
| 7 July 2025 | BTIG | Maintains | Buy | — |
| 7 July 2025 | Cantor Fitzgerald | Downgrade | Neutral | — |
| 7 July 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 July 2025 | William Blair | Downgrade | Market Perform | — |
| 15 May 2025 | Oppenheimer | Maintains | Outperform | — |
| 13 May 2025 | UBS | Maintains | Buy | — |
| 11 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Feb 2025 | UBS | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
JSPR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Jasper Therapeutics, Inc. (JSPR) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.2×
- Price / sales
- —
- Price / book
- 5.2×
- EV / EBITDA
- −0.1×
Cheaper than 77% of US stocks
Cheaper than 20% of US stocks
Cheaper than 62% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −244.2%
- Return on assets
- −112.2%
- Dividend yield
- —
Higher than 5% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
JSPR vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JSPR appears on the weeks it earns a place.
Frequently asked questions about JSPR stock
What is the JSPR stock price forecast for 2026-2027?
The 5 Wall Street analysts covering Jasper Therapeutics, Inc. have a median 12-month price target of $6, with estimates ranging from $1.5 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is JSPR stock a buy right now?
Of the 5 analysts covering Jasper Therapeutics, Inc., 2 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Jasper Therapeutics, Inc. 39 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank JSPR?
As at 1 Aug 2026, Jasper Therapeutics, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).
Will JSPR stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +889.6% from the last close, and Ticker Nerd's factor model ranks Jasper Therapeutics, Inc. 39 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the JSPR stock forecast for 2030?
No analyst covering Jasper Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JSPR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $20 over the next 12 months.
How has JSPR stock performed over the past year?
Jasper Therapeutics, Inc. returned -78.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Jasper Therapeutics, Inc. do?
Jasper Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for disease treatment, particularly in the field of hematopoietic cell transplantation, autoimmune diseases, and chronic immune disorders.
About Jasper Therapeutics, Inc.
Jasper Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for disease treatment, particularly in the field of hematopoietic cell transplantation, autoimmune diseases, and chronic immune disorders. The company's approach relies on targeted technologies aimed at improving the safety and effectiveness of blood and immune system replacement therapies. This is critical in medical procedures like bone marrow transplants where the treatment preconditioning traditionally includes high-dose chemotherapy or radiation, posing significant risks to patients. Jasper Therapeutics strives to provide safer and more effective alternatives, thereby offering a potentially transformative impact on patient outcomes in these sectors. As an entity within the biotechnology industry, its developments have significant implications for healthcare advancements and patient care methodologies. Jasper Therapeutics is strategically positioned within the biotech market, making substantial contributions through its research and development efforts towards better treatment paradigms in its niche areas.
CEO Mr. Jeetinder Singh Mahal M.B.A. · 22 employees · United States · https://jaspertx.com